[OpenAI Acquires Drug Development Collaboration Platform Orchestra Bio] According to an official announcement from OpenAI, the company has acquired the drug development collaboration platform Orchestra Bio. This platform assists biopharmaceutical teams in coordinating complex drug development processes, allowing scientists and project leaders to delegate the monitoring and tracking of research and trials to AI agents. OpenAI stated that it will integrate Orchestra's team and technology with its life sciences research AI models and tools, Rosalind, to help new therapies reach patients more quickly.